Showing 1321-1330 of 5603 results for "".
Treat-to-Target: Are We There Yet?
https://reachmd.com/programs/cme/treat-to-target-are-we-there-yet/51485/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Switching Strategies: Switch or Stay—What’s Your Call?
https://reachmd.com/programs/cme/switching-strategies-switch-or-staywhats-your-call/51487/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Primary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/Review clinical features, diagnostic criteria, and treatment options for PBC, a chronic liver disease primarily affecting women over age 50.Molecular Precision: How Myosin Inhibitors Redefine Control
https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Routes Reconsidered: A Case-Based Debate in SERD Selection
https://reachmd.com/programs/cme/routes-reconsidered-a-case-based-debate-in-serd-selection/39807/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
https://reachmd.com/programs/cme/transforming-care-in-pediatric-patients-with-c3-glomerulopathy-targeting-c3-at-the-source/54143/Join Drs. Daga and Lafayette for a case discussion exploring the optimal use of complement inhibitor therapy in a pediatric patient with C3 glomerulopathy.The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Rethinking Schizophrenia Treatment Through Muscarinic Modulation
https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/Learn expert insights on muscarinic antipsychotics in schizophrenia, including mechanisms, safety, and switching considerations.